# Camostat Mesylate for Protein-losing Enteropathy After Fontan Operation

> **NCT05474664** · PHASE2 · COMPLETED · sponsor: **Seoul National University Hospital** · enrollment: 19 (actual)

## Conditions studied

- Fontan Operation
- Protein-Losing Enteropathy
- Camostat Mesylate

## Interventions

- **DRUG:** Camostat mesylate

## Key facts

- **NCT ID:** NCT05474664
- **Lead sponsor:** Seoul National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-03
- **Primary completion:** 2024-07-12
- **Final completion:** 2024-10-08
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2024-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05474664

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05474664, "Camostat Mesylate for Protein-losing Enteropathy After Fontan Operation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05474664. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*